Moderna. Getting the shots distributed is turning into a feat, too.
Managing that distribution for the government’s Operation Warp Speed program is McKesson (ticker: MCK), and its role has helped lift its stock 22% this year, to $170, compared with the 14% gain of the
Morgan Stanley’s Ricky Goldwasser figures that the Moderna (MRNA) shots alone could be worth as much as $1 billion to McKesson’s 2021 revenue and $1 a share to its earnings. In a Thursday note, she updates her forecasts and reiterates her Buy rating on the stock, which she thinks could reach $219.
McKesson shares were down 0.1%, at $169.83, in recent trading. The S&P 500 was up 0.1%.